[1] Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs. 2003; 3:149−62.
[2] Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132:397−414.
[3] Lesurtel M, Graf R, Aleil B, Tian Y, Jochum W, Gachet C, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006; 312:104−7.
[4] Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006; 169:861−76.
[5] Jang JH, Rickenbacher A, Humar B, Weber A, Raptis DA, Lehmann K, et al. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation. Hepatology. 2012; 56:209−18.
[6] Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008; 68:5152−8.
[7] Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med. 2008; 14:756−61.
[8] Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild PJ, DeOliveira ML, et al. Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res. 2012; 18:5902−10.
[9] Fatima S, Shi X, Lin Z, Chen G, Pan X, Wu JC, et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing beta-catenin. Mol Oncol. 2016; 10:195−212.
[10] Liu S, Miao R, Zhai M, Pang Q, Deng Y, Liu S, et al. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. Oncotarget. 2017; 8:47412−24.
[11] Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, et al. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Eur J Gastroenterol Hepatol. 2016; 28:599−605.
[12] Mamdouh F, Abdel Alem S, Abdo M, Abdelaal A, Salem A, Rabiee A, et al. Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. J Interferon Cytokine Res. 2019; 39:780−5.
[13] Abdel-Hamid NM, Shehata DE, Abdel-Ghany AA, Ragaa A, Wahid A. Serum serotonin as unexpected potential marker for staging of experimental hepatocellular carcinoma. Biomed Pharmacother. 2016; 83:407−11.
[14] Aryal B, Shimizu T, Kadono J, Furoi A, Komokata T, Kitazono I, et al. Post-Resection Exhaustion of Intra-Platelet Serotonin: Also an Indicator of Early Hepatocellular Carcinoma Recurrence? J Cancer. 2017; 8:3984−91.
[15] Padickakudy R, Pereyra D, Offensperger F, Jonas P, Oehlberger L, Schwarz C, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol. 2017; 67:1243−52.
[16] Shu B, Wang S, Deng Y, Zhai M, Liu S. Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe? J Hepatol. 2018;68:1333−4.
[17] Kudo M, Kitano M, Sakurai T, Nishida N. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015; 33: 765−70.
[18] Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993; 9:298−304.
[19] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240:205−13.
[20] Midorikawa Y, Takayama T, Higaki T, Nakayama H, Yamamoto M, Ariizumi S, et al. Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy Jpn J Clin Oncol. 2016; 46:1102−7.
[21] Yagi R, Midorikawa Y, Moriguchi M, Nakayama H, Aramaki O, Yamazaki S, e al. Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria. Surgery. 2018; 163: 1250−6.
[22] Yamagishi S, Midorikawa Y, Nakayama H, Higaki T, Moriguchi M, Aramaki O, et al. Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Hepatol Res. 2019; 49: 432−40.
[23] Lesurtel M, Soll C, Humar B, Clavien PA. Serotonin: a double-edged sword for the liver? Surgeon. 2012; 10:107−13.
[24] Papadimas GK, Tzirogiannis KN, Mykoniatis MG, Grypioti AD, Manta GA, Panoutsopoulos GI. The emerging role of serotonin in liver regeneration. Swiss Med Wkly. 2012; 142:w13548.
[25] Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Tasken KA, Abrahamsson PA. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol. 2011; 29; 436−45.
[26] Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009; 11; R81.
[27] Han S, Park HW, Song JH, Gwak MS, Lee WJ, Kim G, et al. Association Between Intraoperative Platelet Transfusion and Early Graft Regeneration in Living Donor Liver Transplantation. Ann Surg. 2016; 264:1065−72.
[28] Yamazaki S, Takayama T, Mitsuka Y, Aoki M, Midorikawa Y, Moriguchi M, et al. Platelet recovery correlates parenchymal volume recovery after liver resection. Hepatol Res. 2020; 50:620−8.
[29] Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology. 2014; 60:257−66.
[30] Furrer K, Rickenbacher A, Tian Y, Jochum W, Bittermann AG, Käch A, et al. Serotonin reverts age-related capillarization and failure of regeneration in the liver through a VEGF-dependent pathway. Proc Natl Acad Sci U S A. 2011; 108:2945−50.
[31] Nagao Y, Akahoshi T, Kamori M, Uehara H, Hashimoto N, Kinjo N, et al. Liver regeneration is promoted by increasing serotonin content in rat liver with secondary biliary cirrhosis. Hepatol Res. 2011; 41:784−94.
[32] Orvoine RH. Influence of various hexoses and vasoactive agents on osmotically induced oncolysis. Cancer Res. 198;41: 5044−8.
[33] Müller K, Gilbertz KP, Viktor Meineke V. Serotonin and ionizing radiation synergistically affect proliferation and adhesion molecule expression of malignant melanoma cells. J Dermatol Sci. 2012; 68: 89−98.
[34] Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Cell Mol Life Sci. 2008; 65:940−52.